These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

285 related articles for article (PubMed ID: 35908664)

  • 1. Quality by design (QbD) approach in marketing authorization procedures of Non-Biological Complex Drugs: A critical evaluation.
    Zagalo DM; Sousa J; Simões S
    Eur J Pharm Biopharm; 2022 Sep; 178():1-24. PubMed ID: 35908664
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Question-based review for pharmaceutical development: An enhanced quality approach.
    Simões A; Veiga F; Vitorino C
    Eur J Pharm Biopharm; 2024 Feb; 195():114174. PubMed ID: 38160986
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Summary of the EMA Joint Regulators/Industry QbD workshop (London, UK; 28-29 January 2014).
    Cook G; France G; Holte Ø; Lorenti G; Tainsh D
    PDA J Pharm Sci Technol; 2016; 70(2):163-76. PubMed ID: 26797977
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regulatory Science Approach in Pharmaceutical Development of Follow-on Versions of Non-Biological Complex Drug Products.
    Zagalo DM; Simões S; Sousa J
    J Pharm Sci; 2022 Oct; 111(10):2687-2713. PubMed ID: 35901943
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Implementing quality by design for biotech products: Are regulators on track?
    Luciani F; Galluzzo S; Gaggioli A; Kruse NA; Venneugues P; Schneider CK; Pini C; Melchiorri D
    MAbs; 2015; 7(3):451-5. PubMed ID: 25853461
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Roadmap for implementation of quality by design (QbD) for biotechnology products.
    Rathore AS
    Trends Biotechnol; 2009 Sep; 27(9):546-53. PubMed ID: 19647883
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical product development: A quality by design approach.
    Pramod K; Tahir MA; Charoo NA; Ansari SH; Ali J
    Int J Pharm Investig; 2016; 6(3):129-38. PubMed ID: 27606256
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Implementation of Quality by Design (QbD) Principles in Regulatory Dossiers of Medicinal Products in the European Union (EU) Between 2014 and 2019.
    Ter Horst JP; Turimella SL; Metsers F; Zwiers A
    Ther Innov Regul Sci; 2021 May; 55(3):583-590. PubMed ID: 33439461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quality by Design in Pharmaceuticals: A Review of its Impact on Regulatory Compliance and Product Quality.
    Nunavath RS; Singh MT; Jain A; Chakma M; Arivuselvam R; Azeeze MSTA
    Drug Res (Stuttg); 2024 Jan; 74(1):18-23. PubMed ID: 38134919
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Review Experiences and Regulatory Challenges for Pharmaceutical Development in Japan Using a Quality-by-Design Approach.
    Kuno K; Toyoshima S
    Ther Innov Regul Sci; 2016 May; 50(3):368-374. PubMed ID: 30227068
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quality by design (QbD) approaches in current pharmaceutical set-up.
    Mishra V; Thakur S; Patil A; Shukla A
    Expert Opin Drug Deliv; 2018 Aug; 15(8):737-758. PubMed ID: 30044646
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Impact of GAMP 5, data integrity and QbD on quality assurance in the pharmaceutical industry: How obvious is it?
    Pedro F; Veiga F; Mascarenhas-Melo F
    Drug Discov Today; 2023 Nov; 28(11):103759. PubMed ID: 37660982
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The EU regulatory landscape of non-biological complex drugs (NBCDs) follow-on products: Observations and recommendations.
    Klein K; Stolk P; De Bruin ML; Leufkens HGM; Crommelin DJA; De Vlieger JSB
    Eur J Pharm Sci; 2019 May; 133():228-235. PubMed ID: 30953753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Equivalence of complex drug products: advances in and challenges for current regulatory frameworks.
    Hussaarts L; Mühlebach S; Shah VP; McNeil S; Borchard G; Flühmann B; Weinstein V; Neervannan S; Griffiths E; Jiang W; Wolff-Holz E; Crommelin DJA; de Vlieger JSB
    Ann N Y Acad Sci; 2017 Nov; 1407(1):39-49. PubMed ID: 28445611
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Impact of Quality by Design Development on the Review Period of New Drug Approval and Product Quality in Japan.
    Kajiwara E; Kamizato H; Shikano M
    Ther Innov Regul Sci; 2020 Sep; 54(5):1192-1198. PubMed ID: 32865801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From molecule to market access: drug regulatory science as an upcoming discipline.
    Gispen-de Wied CC; Leufkens HGM
    Eur J Pharmacol; 2013 Nov; 719(1-3):9-15. PubMed ID: 23891846
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Quality by design (QbD) in the formulation and optimization of liquid crystalline nanoparticles (LCNPs): A risk based industrial approach.
    Waghule T; Dabholkar N; Gorantla S; Rapalli VK; Saha RN; Singhvi G
    Biomed Pharmacother; 2021 Sep; 141():111940. PubMed ID: 34328089
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Considerations and Regulatory Challenges for Innovative Medicines in Expedited Approval Programs: Breakthrough Therapy and Sakigake Designation.
    Kajiwara E; Shikano M
    Ther Innov Regul Sci; 2020 Jul; 54(4):814-820. PubMed ID: 32557300
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regulatory Considerations, Challenges and Risk-based Approach in Nanomedicine Development.
    Csóka I; Ismail R; Jójárt-Laczkovich O; Pallagi E
    Curr Med Chem; 2021; 28(36):7461-7476. PubMed ID: 33823761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Quality by design in pharmaceutical manufacturing: A systematic review of current status, challenges and future perspectives.
    Grangeia HB; Silva C; Simões SP; Reis MS
    Eur J Pharm Biopharm; 2020 Feb; 147():19-37. PubMed ID: 31862299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.